<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221018056225N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-27</date_registration>
      <primary_sponsor>Bagheiat-allah University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of Low Level Laser Therapy on The Post Midline laparotomy Wound Pain</public_title>
      <acronym></acronym>
      <scientific_title>Determining the effect of low-power laser therapy on midline laparotomy pain compared to placebo in upper and lower gastrointestinal surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66408</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: By Using the online software www.randomizer.org, the patients were divided into two groups of 50 people, control and intervention, in a simple and individual way. Considering that the study is double-blind; The patient and the attending physician as pain evaluators will not know whether the patients belong to the control or intervention groups, Blinding description: Participants and pain evaluators, as well as the researcher of this study, by considering that the randomization of patients is done by the intervention provider, are not aware of which patient received the intervention and which patient received the placebo.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Patients who have been admitted to the Baqiyatallah educational and therapeutic center and have undergone midline laparotomy for elective upper and lower gastrointestinal surgery will be studied. Condition 2: Patients who have been admitted to the Baqiyatallah educational and therapeutic center and have undergone midline laparotomy for elective upper and lower gastrointestinal surgery will be studied. Condition 3: Patients who have been admitted to the Baqiyatallah educational and therapeutic center and have undergone midline laparotomy for elective upper and lower gastrointestinal surgery will be studied. Condition 4: Patients who have been admitted to the Baqiyatallah educational and therapeutic center and have undergone midline laparotomy for elective upper and lower gastrointestinal surgery will be studied. Condition 5: Patients who have been admitted to the Baqiyatallah educational and therapeutic center and have undergone midline laparotomy for elective upper and lower gastrointestinal surgery will be studied.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to receiving the treatments of the first group, the intervention group is also treated with low-power laser. The distance of 2 cm from the wound after removing the surgical dressing will be 0.5 J/cm2 radiation dose. Considering that the radiation cross-section was considered to be 30 square centimeters; According to the formula t = (D. A) / P, the radiation time was calculated for 6 minutes each time. In total, the laser radiation will be done during the first three days after the operation for each patient, and its sequence will be such that the first dose of radiation It will be done after recovery and in the ward, and the next doses will be done at 24-hour intervals until the third day after the operation while in the hospital. Intervention 2: Control group: The first group (control) after the operation receive the usual treatments, including intravenous and oral pain relievers in case of pain, in addition to being treated with a low-power silent laser (Placebo). In total, during the first three days after After the operation, each patient will be treated with placebo three times, and the sequence will be such that the first time will be done after recovery and in the ward, and the next times will be done at intervals of 24 hours until the third day after the operation while in the hospital. will be done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data of this study according to the plan and after the completion of the data analysis so that the patients under study are not identifiable can be received by contacting the person in charge of scientific accountability in case of decision to publish the article in the ICMJE-related journals.

When:
The access period starts 6 months after the publication of the article in ICMJE-related journals.

To whom:
All researchers of university institutes who have published articles in ICMJE-related journals will be able to access the information of this study.

Conditions:
The data and analysis results of this study can only be used for inclusion in review studies.

Where to obtain:
To receive the data or the results of the analysis of this study, please refer to the person responsible for the scientific response of this study, Mr. Dr. Mohammad Madadi Imamchai, with the following contact information.
Address:Baqiyatallah University of Medical Sciences, Department of General Surgery, Azam Ave, South Sheikh Bahai St, Molla Sadra Blvd, Vanak Square, Tehran.
Mobile number: 00989104009204
Workplace phone number: 00982181267609
Fax number: 00982188033539
Email: geniusman68@yahoo.com
Postal code: 1435915371

How to obtain:
The request of receive information can be processed in a period of less than one week after checking the mentioned necessary conditions.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Madadi Emamchai</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Baqiyatallah University of Medical Sciences, Department of General Surgery, Azam Ave, South Sheikh Bahai St, Mollasadra Blvd, Vanak Square, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435915371</zip>
        <telephone>+98 21 8126 7609</telephone>
        <email>Geniusman68@yahoo.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Madadi Emamchai</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Baqiyatallah University of Medical Sciences, Department of General Surgery, Azam Ave, South Sheikh Bahai St, Mollasadra Blvd, Vanak Square, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1435915371</zip>
        <telephone>+98 21 8126 7609</telephone>
        <email>Geniusman68@yahoo.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are in the age range of 30 to 60 years.
Patients who underwent midline laparotomy were selected for elective upper and lower gastrointestinal surgery.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who do not agree to participate in the study.
Patients who, in addition to surgery, have other serious medical problems (ASA III-VI) or suffer from psychotic disorders or drug addiction.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K42</hc_code>
      <hc_code>K43</hc_code>
      <hc_code>K46</hc_code>
      <hc_code>K31</hc_code>
      <hc_code>K25</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Umbilical hernia</hc_keyword>
      <hc_keyword>Ventral hernia</hc_keyword>
      <hc_keyword>Unspecified abdominal hernia</hc_keyword>
      <hc_keyword>Other diseases of stomach and duodenum</hc_keyword>
      <hc_keyword>Gastric ulcer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to receiving the treatments of the first group, the intervention group is also treated with low-power laser. The distance of 2 cm from the wound after removing the surgical dressing will be 0.5 J/cm2 radiation dose. Considering that the radiation cross-section was considered to be 30 square centimeters; According to the formula t = (D. A) / P, the radiation time was calculated for 6 minutes each time. In total, the laser radiation will be done during the first three days after the operation for each patient, and its sequence will be such that the first dose of radiation It will be done after recovery and in the ward, and the next doses will be done at 24-hour intervals until the third day after the operation while in the hospital.</i_keyword>
      <i_keyword>Control group: The first group (control) after the operation receive the usual treatments, including intravenous and oral pain relievers in case of pain, in addition to being treated with a low-power silent laser (Placebo). In total, during the first three days after After the operation, each patient will be treated with placebo three times, and the sequence will be such that the first time will be done after recovery and in the ward, and the next times will be done at intervals of 24 hours until the third day after the operation while in the hospital. will be done.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Midline laparotomy surgery site pain. Timepoint: Before beginning of the intervention, 24, 48, 72 hour's after beginning of the intervention. Method of measurement: visual analogue scale.</prim_outcome>
      <prim_outcome>Local complications of the laparotomy site. Timepoint: Before beginning of the intervention, 24, 48, 72 hour's after beginning of the intervention. Method of measurement: Inspection of the operation site.</prim_outcome>
      <prim_outcome>Serum Inflammatory factors. Timepoint: Before beginning of the intervention, 24, 48, 72 hour's after beginning of the intervention. Method of measurement: Taking daily blood tests.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The amount of painkillers. Timepoint: Before beginning of the intervention, 24, 48, 72 hour's after the start of the intervention. Method of measurement: check the patient's medical record.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bagheiat-allah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-24</approval_date>
        <contact_name>Research Ethics Committees of Baqiyatallah Hospital</contact_name>
        <contact_address>Baqiyatallah University of Medical Sciences, Baqiyatallah hospital, Department of General Surgery, Azam Ave, South Sheikh Bahai St, Molla Sadra Blvd, Vanak Square, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
